key: cord-0777858-4gou86b0
authors: de Melo, Caroline Vilas Boas; Peters, Florence; van Dijken, Harry; Lenz, Stefanie; van de Ven, Koen; Wijsman, Lisa; Gommersbach, Angéla; Schouten, Tanja; van Kasteren, Puck B.; Judith, van den Brand; de Jonge, Jørgen
title: Influenza infection in ferrets with SARS-CoV-2 infection history
date: 2022-03-23
journal: bioRxiv
DOI: 10.1101/2022.03.22.485425
sha: 32a0a6131e15629350fa3122c321891a2167c342
doc_id: 777858
cord_uid: 4gou86b0

Non-pharmaceutical interventions (NPIs) to contain the SARS-CoV-2 pandemic drastically reduced human-to-human interactions, decreasing the circulation of other respiratory viruses as well. As a consequence, influenza virus circulation – normally responsible for 3-5 million hospitalizations per year globally – was significantly reduced. With downscaling the NPI countermeasures, there is a concern for increased influenza disease, particularly in individuals suffering from post-acute effects of SARS-CoV-2 infection. To investigate this possibility, we performed a sequential influenza H1N1 infection 4 weeks after an initial SARS-CoV-2 infection in the ferret model. Upon H1N1 infection, ferrets that were previously infected with SARS-CoV-2 showed an increased tendency to develop clinical symptoms compared to the control H1N1 infected animals. Histopathological analysis indicated only a slight increase for type II pneumocyte hyperplasia and bronchitis. The effects of the sequential infection thus appeared minor. However, ferrets were infected with B.1.351-SARS-CoV-2, the beta variant of concern, which replicated poorly in our model. The histopathology of the respiratory organs was mostly resolved 4 weeks after SARS-CoV-2 infection, with only reminiscent histopathological features in the upper respiratory tract. Nevertheless, SARS-CoV-2 specific cellular and humoral responses were observed, confirming an established infection. Thus, there may likely be a SARS-CoV-2 variant-dependent effect on the severity of disease upon a sequential influenza infection as we observed mild effects upon a mild infection. It, however, remains to be determined what the impact is of more virulent SARS-CoV-2 variants. Importance During the COVID-19 pandemic, the use of face masks, social distancing and isolation were not only effective in decreasing the circulation of SARS-CoV-2, but also in reducing other respiratory viruses such as influenza. With less restrictions, influenza is slowly returning. In the meantime, people still suffering from long-COVID, could be more vulnerable to an influenza virus infection and develop more severe influenza disease. This study provides directions to the effect of a previous SARS-CoV-2 exposure on influenza disease severity in the ferret model. This model is highly valuable to test sequential infections under controlled settings for translation to humans. We could not induce clear long-term COVID-19 effects as SARS-CoV-2 infection in ferrets was mild. However, we still observed a slight increase in influenza disease severity compared to ferrets that had not encountered SARS-CoV-2 before. It may therefore be advisable to include long-COVID patients as a risk group for influenza vaccination.

Two years after the emergence of SARS-CoV-2 in late 2019, the causative agent of COVID-50 19 is still an important global health and economic problem. In order to mitigate virus 51 transmission, a set of non-pharmaceutical interventions (NPIs), such as the use of face masks, 52 physical distancing and travel restrictions were adopted worldwide, leading to a considerable 53 decrease in social interactions [1] . The unprecedented reduced human interaction was not only 54 effective against SARS-CoV-2 transmission, but it also resulted in an almost complete absence 55 of circulation of several other respiratory viruses [2] [3] [4] . For influenza virus, for example, the 56 recorded peak of over 40.000 weekly cases in the global 2019-2020 influenza season, 57 dramatically decreased in incidence from March 2020 to essentially zero in the following 58 months, leading to the absence of the global 2020-2021 influenza season [5] . With the release 59 of NPIs and subsequent renewed circulation of respiratory viruses, there is a concern that 60 influenza infection might lead to more severe disease in individuals previously exposed to 61 SARS-CoV-2. There are at least two reasons for this: (1) the interrupted seasonal exposure has 62 resulted in reduced immunity in the population, which is therefore more susceptible [6] ; and 63 (2), residual effects of COVID-19 can have a negative clinical impact on a sequential 64 respiratory viral infection, such as influenza. 65 Fatigue, dyspnea, and chest pain are commonly reported after cleared SARS-CoV-2 infection 66 [7]. These long-term effects of COVID-19, so-called post-acute COVID-19 or long-COVID 67 syndrome are possible clinical repercussions of pulmonary sequelae of a SARS-CoV-2 68 infection [8, 9] . The only evidence for increased disease in a situation where SARS-CoV-2 and 69 influenza co-circulated goes back to the beginning of the SARS-CoV-2 pandemic, when 70 influenza virus was still circulating. It was then observed that a higher risk for severe outcome 71 was associated with influenza co-infection in lethal cases of . In the current 72 5 stage, however, it is still unclear whether a recent SARS-CoV-2 infection history could 73 negatively impact a sequential influenza infection. 74 Animal models are an ideal tool to investigate combinations of infections under controlled 75 conditions. Multiple animal models of COVID-19 are currently available [14] , but not all of 76 them are equally suitable for modelling influenza disease. So far, co-infection studies with 77 SARS-CoV-2 and influenza A virus (IAV) in hamster and K18-ACE2 mouse models indicate 78 more severe pneumonia [15] [16] [17] and confirm the initial findings in humans [18] . Ferrets co-79 infected with SARS-CoV-2 and IAV developed increased weight loss and enhanced 80 inflammation in the nasal cavity and lungs [19] . In transgenic hACE2 mice, more severe lung 81 damage upon a sequential infection with H1N1 with a brief time interval (7 dpi) and during the to provide evidence to support influenza vaccination as a strategy for mitigating the said severe 98 effects. 167 Twelve ferrets were infected intranasally (i.n.) with 10 7 TCID50 of SARS-CoV-2 beta VOC 168 diluted in phosphate buffered saline (PBS) on day 0. An inoculum volume of 1 mL was used, For the presence of alveolar oedema and type II pneumocyte hyperplasia we scored: 0, 1 (1-237 25%), 2 (25-50%) or 3 (>50%). The presence of alveolar hemorrhage we scored: 0, no; 1, yes.

For the extent of peribronchial/perivascular oedema we scored: 0, no, 1, yes. Finally, for the 239 extent of peribronchial, peribronchiolar, and perivascular infiltrates we scored: 0, none; 1, one 240 to two cells thick; 2, three to ten cells thick; 3, more than ten cells thick. The average scores 241 for size and severity of inflammation of the different slides provided the total score per animal. 311 To evaluate the impact of a previous SARS-CoV-2 infection on a sequential influenza infection 312 during the post-acute phase, we first studied viral replication and clinical signs in two groups 313 of male ferrets that were infected with SARS-CoV-2 beta VOC during a 4 week period. In observed by TCID50 determination in nose swabs (peak at day 5, 1.6 ± 0.2 logTCID50/mL) and 325 throat swabs (peak at day 3, 1.8 ± 0.2 logTCID50/mL) (figure 1d). Viral RNA was not detected 326 in trachea or lung at day 28, but low copy numbers were found in the nasal turbinates of two 327 out of six ferrets (figure 1e).

The clinical signs observed in SARS-CoV-2-infected ferrets were mild and of low frequency. of SARS-CoV-2 beta VOC were found from 14 d.p.i. and reached a plateau on 21-28 d.p.i.

(figure 3d). 361 We next investigated if influenza virus-induced pathology and disease are enhanced during the 2 exposure (six out of six ferrets, 100%) in comparison to four out of five ferrets (80%) ferrets 383 exposed to H1N1 only on day 4. On day 5, clinical signs were only observed in sequentially 384 infected ferrets (SARS-CoV-2/H1N1), with more pronounced labored breathing (five out of 385 six ferrets, 83%) and decreased behavioral activity (two out of six ferrets, 33%) while H1N1-386 infected ferrets without SARS-CoV-2 prior exposure were free of clinical signs. 388 Because prior exposure to SARS-CoV-2 appeared to marginally worsen influenza disease 389 symptoms, we wondered if differential pathology could be observed in the respiratory tract. In variant in female ferrets, with a 100-times lower dose than that we used in this study [34] .

Using a high infectious dose (10 7 TCID50/mL) in male ferrets, we found that the beta VOC and no histopathology alterations were found in the lower respiratory tract. We assume, 455 however, that the absence of pathology in the present study is due to the low level of productive 456 infection when using the beta VOC, since effective SARS-CoV-2 viral replication frequently 457 resulted in pathology manifestation in ferrets in other studies [19, 22, 23, 29, 30, 41] .

It has been shown that co-infection between influenza and SARS-CoV-2 results in more severe 459 disease in animal models through enhanced lung damage [16, 17, 19, 42] . This simultaneous 460 infection was also reported in human patients [10, 11, 43] . In our study, we looked at the 461 effects of a sequential influenza infection during the post-acute phase of SARS-CoV-2 (28 462 days), as an influenza infection is less likely to happen simultaneously or shortly after a SARS- 

The Efficacy of Lockdown Against COVID-19: A Cross-498

Country Panel Analysis. Appl Health Econ Health Policy

Physical distancing in schools for SARS-CoV-2 and the resurgence of 500 rhinovirus

Impact of COVID-19 outbreaks and interventions on influenza in China 502 and the United States

Non-pharmaceutical interventions used for COVID-19 had 504 a major impact on reducing influenza in China in 2020

Which influenza viruses will emerge following the SARS-507

CoV-2 pandemic? Influenza Other Respir Viruses

Persistent Symptoms in Patients After Acute COVID-19

Incidence, co-occurrence, and evolution of long-COVID features: A 511 6-month retrospective cohort study of 273,618 survivors of COVID-19

Immune signatures underlying post-acute COVID-19 lung sequelae

High prevalence of SARS-CoV-2 and influenza A virus

coinfection in dead patients in Northeastern Iran

The epidemiology and clinical characteristics of co-infection of SARS-519

CoV-2 and influenza viruses in patients during COVID-19 outbreak

COVID-19 and Influenza Co-Infection: Report of Three Cases. Cureus

Influenza and COVID-19 coinfection: Report of six cases and review 524 of the literature

Animal models for COVID-19

Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-528 19 pathogenesis in a mammalian model, and co-vaccination as an effective method of 529 prevention of COVID-19 and influenza

Coinfection by Severe Acute Respiratory Syndrome Coronavirus 2 532 and Influenza A(H1N1)pdm09 Virus Enhances the Severity of

Coinfection with influenza A virus enhances SARS-CoV-2 infectivity

The clinical characteristics of pneumonia patients coinfected with 2019 537 novel coronavirus and influenza virus in Wuhan

SARS-CoV-2 and Influenza A virus Co-infections in Ferrets

H1N1 exposure during the convalescent stage of SARS-CoV-2 infection 542 results in enhanced lung pathologic damage in hACE2 transgenic mice. Emerg 543 Microbes Infect

Susceptibility of ferrets, cats, dogs, and other domesticated animals to 545 SARS-coronavirus 2

Increased lethality in influenza and SARS-CoV-2 coinfection is 594 prevented by influenza immunity but not SARS-CoV-2 immunity

Co-infection with COVID-19 and influenza A virus in two died 597 patients with acute respiratory syndrome, Bojnurd, Iran

SARS-CoV-2 cell tropism and multiorgan infection

Influenza A viruses target type II pneumocytes in the human 604 lung

Figure 1. Study design and SARS-CoV-2 (B.1.351, beta VOC) viral load. (a) Male ferrets 610 were infected intranasally (i.n) with SARS-CoV-2 (B.1.351, beta VOC)

Two groups of six ferrets each were infected with beta 613 VOC on Day 0. One of these groups was followed up to 28 days post-infection (d.p.i.) and 614 then euthanized (black cross). The other group was sequentially infected with H1N1 on days 615 29/30. One group of five ferrets was single-infected with H1N1 at the same timepoint. H1N1-616 and mock

618 orange dots) and mock-infected ferrets (n=3, black squares). (b) Beta VOC viral RNA 619 detected 0, 3, 5, 9 and 29 d.p.i. Only the remaining six beta VOC

Beta VOC subgenomic RNA detected by RT-PCR (c) and viral replication detected by 622 TCID50 assay (d) in nose and throat swabs 3 and 5 d.p.i. (e) Beta VOC viral RNA in lung, 623 trachea and nasal turbinates 28 d.p.i. by RT-PCR. Horizontal dotted lines depict the limit of 624 detection by RT-qPCR, set at a Ct-value of 40 (b, c and e) and 1.3 log TCID50/mL for 625 TCID50 assay

Figure 2. Clinical signs and histopathology in post-acute SARS-CoV-2 (B.1.351, beta

14 and 21 days post-infection (d.p.i.). (b) Differences (Δ) in body 631 temperature up to 28 d.p.i. of beta VOC infected ferrets (n=5) relative to the baseline 632 31 measurements recorded over a period of five days prior to infection. (c) Relative lung weight 633 (RLW, %) of the body weight upon euthanasia on 28 d.p.i. of beta VOC-infected ferrets 634 (n=6). The RLW is comparable to RLW of mock-infected ferrets (fig 4d). (d-e) Categorical 635 heatmaps of histopathology represented in semi-quantitative intensity score, with color 636 shading from blue (0) to red (3), or qualitative score of absence (0, blue) or presence (1, red), 637 where indicated. (d) Lung histopathology and (e) histopathology scoring of inflammation of 638 trachea (tracheitis) and nasal turbinates (rhinitis) of six SARS-CoV-2-infected ferrets. Data is 639 visualized as mean with standard deviation and dots represent individual observations

Cellular and humoral responses in SARS-CoV-2 (B.1.351, beta VOC) 644 experimental model. (a) Cellular responses in PBMC on 0, 14, 21 and 28 days post-645 infection (d.p.i.) measured by IFNγ ELISpot against SARS-CoV-2 alpha VOC

culture-acquired mutation in the ORF1a region) and beta VOC, and SARS-CoV-2 peptide 647 pools spanning spike protein (amino acid ranges 1-158 and 159-315), nucleocapsid protein 648 (N) and RNA-dependent RNA polymerase (RdRp) -non

Stimulations with mumps virus and HIV peptide pool were used as negative controls for virus 650 and peptide pool stimulations, respectively. (b) Gating strategy of immunophenotyping of 651

The mock-infected group was not 653 sampled due to its continuation in the study to serve as a control group for the subsequent 654 H1N1 infection. (d) Humoral responses measured by ELISA assay. Optical density (O.D.) 655 values evidence antibody responses against spike and receptor binding domain proteins of 656 beta VOC on 0, 14, 21 and 28 d.p.i. Data is visualized as median (horizontal line, a) or mean 657 (bar or connecting line, c and d) with standard deviation and dots represent individual 658 observations

Figure 4. H1N1 influenza virus infection and disease in ferrets previously exposed to 661

H1N1 influenza viral load, virus replication and clinical 662 disease in ferrets infected with H1N1 influenza virus only (H1N1, n=5, green triangles), in 663 ferrets previously infected with SARS-CoV-2 beta VOC (SARS-CoV-2/H1N1, n=6, blue 664 dots), and in mock-infected ferrets (n=3, black squares). (a) H1N1 viral RNA

H1N1 virus replication detected by TCID50 assay in nose and throat swabs 666 on 0, 2, 4 and 5 days post infection (d.p.i.). (c) H1N1 viral RNA detected by RT-PCR and 667 viral replication assessed by TCID50 in lung

Horizontal dotted lines depict the limit of detection by RT-PCR and TCID50 assay

Percentual body 670 weight variation relative to weight on the day of infection (day 0) of H1N1-or mock-infected 671 ferrets on 0, 2, 4 and 5 d.p.i. (f) Differences (Δ) in body temperature up to 5 d.p.i. relative to 672 the baseline measurements recorded five days prior to infection. (g) Recorded clinical signs 673 of influenza disease of decreased activity and labored breathing. Percentage of ferrets that 674 developed the cited clinical signs in the different groups on 4 and 5 d.p.i. Data is visualized 675 as mean and datapoints represent individual observations (a-d)

Histopathology of H1N1 infection in ferrets previously exposed to SARS-CoV-679 2 (B.1.351, beta VOC)

Histopathology scoring of inflammation of trachea (tracheitis) and nasal turbinates (rhinitis)

Type II pneumocyte hyperplasia and severity of bronchitis in ferrets infected with H1N1 684 influenza virus only (H1N1, n=5, green triangles), or in ferrets previously infected with 685